Correlation between serum level of chemokine (C-C motif) ligand 18 and poor prognosis in breast cancer

J.H. Sun, N. Fan, Y. Zhang
2016 Genetics and Molecular Research  
In this study, we investigated the correlation between serum chemokine (C-C motif) ligand 18 and the prognosis as well as clinical characteristics of breast cancer. Blood samples from 207 breast cancer patients, 126 individuals with benign breast tumors, and 93 healthy women were collected. Serum CCL-18 expression was detected by enzyme-linked immunosorbent assay. Mann-Whitney's U tests were carried out to analyze the relationship between serum CCL-18 and clinicopathological variables. The
more » ... n-Meier method was used to evaluate the overall survival (OS), whereas differences between groups were analyzed by log-rank tests. The COX proportional hazard regression model was used to determine the association between clinicopathological characteristics and survival. We found that serum CCL-18 was significantly higher in breast cancer patients (290.06 ± 89.52 pg/mL) as compared to that in individuals with benign tumors (170.14 ± 26.57 pg/mL) or healthy women (119.36 ± 38.77 pg/mL) (P 2 J.H. Sun et al. Genetics and Molecular Research 15 (3): gmr.15038632 < 0.05). Serum CCL-18 was correlated with clinical cancer stages (P = 0.007), and was associated with advanced cancer stage (P < 0.05). The 5-year OS rate of breast cancer patients with high serum CCL-18 was 35.9% (HR = 3.908, 95%CI = 2.546-12.090, P < 0.05), which was significantly lower as compared to that for patients with low serum CCL-18 (85.5%). Based on our results, we conclude that CCL-18 is a prognostic biomarker in patients with advanced breast cancer in Chinese patients.
doi:10.4238/gmr.15038632 pmid:27706714 fatcat:np25uqczivbnhm35ov37giuls4